Introduce some important element we need for our body.
1. Carbohydrates
This is one of the elements very important for our brain
2.Protein
This is the major element to produce cell.
3.Calcium
99% of Calcium are inside our bone and teeth.
4.Magnesium
To help our body to absorb Calcium
5.Iron
The element to build up the blood so that the blood is enough to carry the oxygen.
6.Vitamin A
Major factor for our eyes and skin
7.Vitamin B-Complex
It represents the Metabolism
8.Vitamin C
Provide better absorption of Calcium, Magnesium & Iron. Also increase the immunity.
9.Vitamin D
Major elements to develop our bone and teeth.
10.Vitamin E
It is the element for cell to maintain in good condition.
11.Vitamin K
Function as clotting. To clot the blood when our body get cut, this is to avoid blood loss.
12.Essential Fatty Acid
Build the membrane
13.Folate
Good for our memory and heart
14.Dietary Fibre
Help in better absorption and Excretion
What kind of Nutrition do we need?
Breast Cancer - Prognosis
A prognosis is the medical team's "best guess" in how cancer will affect a patient. There are many prognostic factors associated with breast cancer: staging, tumour size and location, grade, whether disease is systemic (has metastasized, or traveled to other parts of the body), recurrence of the disease, and age of patient.
Stage is the most important, as it takes into consideration size, local involvement, lymph node status and whether metastatic disease is present. The higher the stage at diagnosis, the worse the prognosis. Larger tumours, invasiveness of disease to lymph nodes, chest wall, skin or beyond, and aggressiveness of the cancer cells raise the stage, while smaller tumours, cancer-free zones, and close to normal cell behaviour (grading) lower it.
Grading is based on how cultured biopsied cells behave. The closer to normal cancer cells are, the slower their growth and a better prognosis. If cells are not well differentiated, they appear immature, divide more rapidly, and tend to spread. Well differentiated is given a grade of 1, moderate is grade 2, while poor or undifferentiated is given a higher grade of 3 or 4 (depending upon the scale used).
Younger women tend to have a poorer prognosis than post-menopausal women due to several factors. Their breasts are active with their cycles, they may be nursing infants, and may be unaware of changes in their breasts. Therefore, younger women are usually at a more advanced stage when diagnosed.
The presence of estrogen and progesterone receptors in the cancer cell, while not prognostic, is important in guiding treatment. Those who do not test positive for these specific receptors will not respond to hormone therapy.
Likewise, HER2/neu status directs the course of treatment. Patients whose cancer cells are positive for HER2/neu have more aggressive disease and may be treated with trastuzumab, a monoclonal antibody that targets this protein.
Psychological aspects of diagnosis and treatment
The emotional impact of cancer diagnosis, symptoms, treatment, and related issues can be severe. Most larger hospitals are associated with cancer support groups which can help patients cope with the many issues that come up in a supportive environment with other people with experience with similar issues. Online cancer support groups are also very beneficial to cancer patients, especially in dealing with uncertainty and body-image problems inherent in cancer treatment.
Not all breast cancer patients experience their illness in the same manner. Factors such as age can have a significant impact on the way a patient copes with a breast cancer diagnosis. For example, a recent study conducted by researchers at the College of Public Health of the University of Georgia showed that older women may face a more difficult recovery from breast cancer than their younger counterparts. As the incidence of breast cancer in women over 50 rises and survival rates increase, breast cancer is increasingly becoming a geriatric issue that warrants both further research and the expansion of specialized cancer support services tailored for specific age groups.
Racial disparities in diagnosis and treatment
Several studies have found that black women in the U.S. are more likely to die from breast cancer even though white women are more likely to be diagnosed with the disease. Even after diagnosis, black women are less likely to get treatment compared to white women. Scholars have advanced several theories for the disparities, including inadequate access to screening, reduced availability of the most advanced surgical and medical techniques, or some biological characteristic of the disease in the African American population. Some studies suggest that the racial disparity in breast cancer outcomes may reflect cultural biases more than biological disease differences. Research is currently ongoing to define the contribution of both biological and cultural factors.
Breast Cancer - Treatment
The mainstay of breast cancer treatment is surgery when the tumor is localized, with possible adjuvant hormonal therapy (with tamoxifen or an aromatase inhibitor), chemotherapy, and/or radiotherapy. At present, the treatment recommendations after surgery (adjuvant therapy) follow a pattern. This pattern is subject to change, as every two years, a worldwide conference takes place in St. Gallen, Switzerland, to discuss the actual results of worldwide multi-center studies. Depending on clinical criteria (age, type of cancer, size, metastasis) patients are roughly divided to high risk and low risk cases, with each risk category following different rules for therapy. Treatment possibilities include radiation therapy, chemotherapy, hormone therapy, and immune therapy.
In planning treatment, doctors can also use PCR tests like Oncotype DX or microarray tests like MammaPrint that predict breast cancer recurrence risk based on gene expression. In February 2007, the MammaPrint test became the first breast cancer predictor to win formal approval from the Food and Drug Administration. This is a new gene test to help predict whether women with early-stage breast cancer will relapse in 5 or 10 years, this could help influence how aggressively the initial tumor is treated.
Lung Cancer - Staging
Staging is the extent of the spread of cancer definition method. Staging is very important, it is because of your recovery and treatment may depend on the profile of your cancer staging. For example, a period of cancer may be the best treatment, while the other would be preferable in the treatment of chemotherapy and radiotherapy. Small-cell and non-small cell lung cancer staging system is not the same.
Patients with lung cancer treatment and prognosis (survival may Overview) depends largely on the stage of cancer and cell types. CT, MRI, scans, bone marrow biopsy, mediastinal microscope and hematology checks can be used for cancer staging.
Be sure to let your doctor you can understand the way in which you explain your view, to decide which treatment best suited to your personal medical situation.
Non-small cell lung cancer staging:
Most often used to describe non-small cell lung cancer (NSCLC) is the growth and spread of the TNM staging system, also called the American Joint Committee on Cancer (AJCC). In the TNM staging, combined with the tumor, nearby lymph nodes and distant organs transfer of information, which used to refer to specific phases of the TNM grouping. Packet staging and the use of digital 0 Roman numerals I to IV to describe.
T representative tumor (in the lungs, as well as the size and extent of the spread of approaching organ), the representative lymph node spread of N, M said metastasis (spread to distant organs).
Non-small cell lung cancer staging T: T classification according to the size of lung cancer in the lungs and the proliferation of location, spread to the extent of approaching organizations.
Tis
- Cancer confined to the airway lining cells pathway. Not spread to the other lung tissue, lung cancer is often called carcinoma in situ.
T1
- Tumors less than 3 cm (slightly less than 11 / 4 inches), did not spread to visceral pleural (lung wrapped with the membrane), and did not affect the main bronchus.
T2
- Cancer one or more of the following characteristics:
- greater than 3 cm
- main bronchial involvement, but from the carina (trachea into place around the main bronchus) more than 2 cm (about 3 / 4 inches).
- Already spread to the visceral pleura
- Cancer partial obstruction of the airway, but did not cause lung or in proper pneumonia
T3
- Cancer one or more of the following characteristics:
- Spread to the chest wall, diaphragm (to be separate from the chest and abdominal respiratory muscle), mediastinal pleura (the gap between the lungs wrapped with the membrane), or layer of pericardial (heart wrapped membrane).
- Side of the main bronchial involvement from the carina (trachea into place around the main bronchus) less than 2 cm (about 3 / 4 inches) but do not include the carina.
- Into the airway has been long enough to cause lung or all in proper pneumonia.
T4
- Cancer one or more of the following characteristics:
- Spread to mediastinal (sternum after the gap in front of the heart), heart, trachea, esophagus (connecting hose pipe and the stomach), spine, or carina (trachea into place around the main bronchus).
- With a lobe, there are two or more independent of tumor nodules
- With malignant pleural effusion (fluid around the lung, cancer cells contain).
Non-small cell lung cancer classification N
N staging of cancer depends on the violation of the lymph nodes near.
N0: cancer has not spread to lymph nodes
N1: the proliferation of lymph node cancer confined to the lungs, hilar lymph nodes (located in bronchial pulmonary enter the local environs). Limited to the lymph node metastasis from lung ipsilateral.
N2: carina cancer has spread to lymph nodes (around tracheal bronchus into position around), or mediastinal lymph node (sternum after heart before the gap). Limited to the lymph nodes involved with ipsilateral lung.
N3: Cancer has spread to the ipsilateral or contralateral supraclavicular lymph node, and (or) from spreading to the contralateral lung hilar or mediastinal lymph nodes.
Table 1: Non-small cell lung cancer group stages
Non-small cell lung cancer staging M
M phases depends on whether the cancer organization or transferred to distant organs.
M0: no distant proliferation.
M1: cancer has spread to one or more distant sites. Other sites include distant lobe, exceeding by more than N staging, and the lymph nodes or other organs, such as the liver, bone or brain.
Non-small cell lung cancer staging groups: Once the T, N and M phases clear, and the combination of these messages (phased organization) would be a clear integrated phases 0, I, II, III or IV period (see table 1). Staging relatively low patient survival prospects good.
Stage small cell lung cancer
Although small cell lung cancer can be as non-small cell lung cancer the same stage, but doctors found that the vast majority of physicians two more simple system in the treatment of a better option. The system will be divided into small-cell lung cancer, "the deadline" and "extensive" period (also called the proliferation of period).
Deadline that the cancer is limited to the lung and lymph nodes only side in the same side of the chest.
If the cancer spread to the other side of the lung, chest or contralateral lymph nodes or distant organs, or is enveloping the pulmonary malignant pleural effusion, called extensive period.
Breast Cancer - Staging
Breast cancer is staged according to the TNM system, updated in the AJCC Staging Manual, now on its sixth edition. Prognosis is closely linked to results of staging, and staging is also used to allocate patients to treatments both in clinical trials and clinical practice. The information for staging is as follows:
TX: Primary tumor cannot be assessed. T0: No evidence of tumor. Tis: Carcinoma in situ, no invasion T1: Tumor is 2 cm or less T2: Tumor is more than 2 cm but not more than 5 cm T3: Tumor is more than 5 cm T4: Tumor of any size growing into the chest wall or skin, or inflammatory breast cancer
NX: Nearby lymph nodes cannot be assessed N0: Cancer has not spread to regional lymph nodes. N1: Cancer has spread to 1 to 3 axillary or one internal mammary lymph node N2: Cancer has spread to 4 to 9 axillary lymph nodes or multiple internal mammary lymph nodes N3: One of the following applies:
Cancer has spread to 10 or more axillary lymph nodes, or Cancer has spread to the lymph nodes under the clavicle (collar bone), or Cancer has spread to the lymph nodes above the clavicle, or Cancer involves axillary lymph nodes and has enlarged the internal mammary lymph nodes, or Cancer involves 4 or more axillary lymph nodes, and tiny amounts of cancer are found in internal mammary lymph nodes on sentinel lymph node biopsy.
MX: Presence of distant spread (metastasis) cannot be assessed. M0: No distant spread. M1: Spread to distant organs, not including the supraclavicular lymph node, has occurred
Summary of stages:
Stage 0 - Carcinoma in situ
Stage I - Tumor (T) does not involve axillary lymph nodes (N).
Stage IIA – T 2-5 cm, N negative, or T <2 cm and N positive.
Stage IIB – T > 5 cm, N negative, or T 2-5 cm and N positive (< 4 axillary nodes).
Stage IIIA – T > 5 cm, N positive, or T 2-5 cm with 4 or more axillary nodes
Stage IIIB – T has penetrated chest wall or skin, and may have spread to < 10 axillary N
Stage IIIC – T has > 10 axillary N, 1 or more supraclavicular or infraclavicular N, or internal mammary N.
Stage IV – Distant metastasis (M)
Breast lesions are examined for certain markers, notably sex steroid hormone receptors. About two thirds of postmenopausal breast cancers are estrogen receptor positive (ER+) and progesterone receptor positive (PR+).[83] Receptor status modifies the treatment as, for instance, only ER-positive tumors, not ER-negative tumors, are sensitive to hormonal therapy.
The breast cancer is also usually tested for the presence of human epidermal growth factor receptor 2, a protein also known as HER2, neu or erbB2. HER2 is a cell-surface protein involved in cell development. In normal cells, HER2 controls aspects of cell growth and division. When activated in cancer cells, HER2 accelerates tumor formation. About 20-30% of breast cancers overexpress HER2. Those patients may be candidates for the drug trastuzumab, both in the postsurgical setting (so-called "adjuvant" therapy), and in the metastatic setting.
